中基健康(000972.SZ):終止發行股份購買資產並募集配套資金事項
格隆匯3月1日丨中基健康(000972.SZ)公佈,公司於2024年2月28日召開第九屆董事會第四十次臨時會議及第九屆監事會第二十二次臨時會議,審議通過了《關於終止發行股份購買資產並募集配套資金暨關聯交易的議案》,同意公司終止發行股份購買資產並募集配套資金暨關聯交易事項。
此前公吿稱,公司擬通過發行股份方式收購新疆新糧豔陽天番茄股份有限公司100%股權,同時公司擬向不超過35名特定投資者非公開發行股份募集配套資金(以下簡稱"本次交易")。本次交易構成關聯交易,構成重大資產重組,不構成重組上市。本次交易不會導致公司實際控制人變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.